Professor of Medicine
Pulmonology
Dr. Imre Noth, MD
Imre Noth works in the field of Pulmonology. He went to University of Arizona College of Medicine - Tucson. University of Arizona College of Medicine - Tucson has a rank of 67 in research and a 42 in primary care He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Imre Noth is a published physician. He published 34 publications, including: 'A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis.' He accepts Medicare.
Publications
- Sphingosine-1-phosphate lyase is an endogenous suppressor of Pulmonary fibrosis: role of S1P signalling and autophagy.
- Oral immunotherapy with type V collagen in idiopathic Pulmonary fibrosis.
- Effect of telomere length on survival in patients with idiopathic Pulmonary fibrosis: an observational cohort study with independent validation.
- Lung microbiome and disease progression in idiopathic Pulmonary fibrosis: an analysis of the COMET study.
- The Mitochondrial Cardiolipin Remodeling Enzyme Lysocardiolipin Acyltransferase (LYCAT) is a Novel Target in Pulmonary Fibrosis.
- Idiopathic Pulmonary fibrosis: Early detection and referral.
- Reply: rationale for anticoagulant therapy of Pulmonary fibrosis.
- Idiopathic Pulmonary fibrosis: time to get personal?
- Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis.
- Future Directions in Idiopathic Pulmonary Fibrosis Research: An NHLBI Workshop Report.
- Idiopathic Pulmonary Fibrosis and Gastroesophageal Reflux. Implications for Treatment.
- Functional promoter variants in sphingosine 1-phosphate receptor 3 associate with susceptibility to sepsis-associated acute Respiratory distress syndrome.
- Anti-acid treatment and disease progression in idiopathic Pulmonary fibrosis: an analysis of data from three randomised controlled trials.
- Genetic variants associated with idiopathic Pulmonary fibrosis susceptibility and mortality: a genome-wide association study.
- Reply: A Placebo-controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis: A Hidden Subgroup?
- The Pulmonary Side of Reflux Disease: from Heartburn to Lung Fibrosis.
- Targeting sphingosine kinase 1 attenuates bleomycin-induced Pulmonary fibrosis.
- Peripheral blood gene expression as a novel genomic biomarker in complicated Sarcoidosis.
- The utility of albuterol nebulized with heliox during acute Asthma exacerbations.
- Short duration exercise increases breath hydrogen excretion after lactulose ingestion: description of a new phenomenon.
- Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic Pulmonary fibrosis.
- Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis Lung disease.
- Conventional transbronchial needle aspiration decreases the rate of surgical sampling of intrathoracic lymphadenopathy.
- Acute exacerbations of idiopathic Pulmonary fibrosis.
- Recent advances in idiopathic Pulmonary fibrosis.
- The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic Pulmonary fibrosis.
- A variant in the promoter of MUC5B and idiopathic Pulmonary fibrosis.
- Autoimmune-featured interstitial Lung disease: a distinct entity.
- Interstitial Lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment.
- Where next for gene expression profiling? So much promise.
- Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic Pulmonary fibrosis.
- Levels of soluble human leukocyte antigen-G are increased in Asthmatic airways.
- A functional genomic model for predicting prognosis in idiopathic Pulmonary fibrosis.
Schools
University Of Arizona College Of Medicine
Uc Davis Med Center
University Ca Davis Med Center
University Of Chicago Hosps
University of Chicago
Procedures Preformed
- Bronchoscopy
- Thoracentesis
- Ventilation Management
Conditions Treated
- Acidosis
- Alkalosis
- Asthma
- Atelectasis
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
University of California Davis -
University of Arizona College of Medicine - Tucson
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1730241282 | |
| NPPES Provider LastName | NOTH | |
| NPPES Provider FirstName | IMRE | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Critical Care (Intensivists) | |
| Total Claim Count | 152.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730241282 |
| Last Name Of The Provider | NOTH |
| First Name Of The Provider | IMRE |
| View All |
Similar Doctors
|
Dr. Madelyn D. Kahana, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas Hogarth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Russell Hall, MD |
|
|
Dr. Mark E. Nunnally, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven R. White, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven Dudek, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Holly J. Humphrey, MD |
|
|
Dr. Brian Gehlbach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John F. McConville, MD |
|
|
Kieran J. Nicholson, MB |